{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:57:21Z","timestamp":1793505441175,"version":"4.5.0"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T00:00:00Z","timestamp":1731715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T00:00:00Z","timestamp":1731715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005230","name":"Natural Science Foundation of Chongqing Municipality","doi-asserted-by":"publisher","award":["NO. cstc2021jcyj-msxmX0179"],"award-info":[{"award-number":["NO. cstc2021jcyj-msxmX0179"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00277-024-06079-y","type":"journal-article","created":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T01:29:44Z","timestamp":1731720584000},"page":"1427-1442","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effect of POD24 on the prognosis of follicular and other indolent B-cell non-hodgkin lymphomas"],"prefix":"10.1007","volume":"104","author":[{"given":"Xiaoyan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,16]]},"reference":[{"key":"6079_CR1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.21357","volume":"66","author":"LR Teras","year":"2016","unstructured":"Teras LR, DeSantis CE, Cerhan JR et al (2016) <ArticleTitle Language=\u201cEn\u201d>2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 66:443\u2013459. https:\/\/doi.org\/10.3322\/caac.21357","journal-title":"CA Cancer J Clin"},{"key":"6079_CR2","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.3324\/haematol.2016.148809","volume":"101","author":"MP Anamarija","year":"2016","unstructured":"Anamarija MP, Jacques D, Bharat NN et al (2016) Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project. Haematologica 101:1244\u20131250. https:\/\/doi.org\/10.3324\/haematol.2016.148809","journal-title":"Haematologica"},{"key":"6079_CR3","doi-asserted-by":"publisher","first-page":"5210","DOI":"10.1182\/bloodadvances.2022007990","volume":"6","author":"AM Tun","year":"2022","unstructured":"Tun AM, Khurana A, Mwangi R et al (2022) Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study. Blood Adv 6:5210\u20135221. https:\/\/doi.org\/10.1182\/bloodadvances.2022007990","journal-title":"Blood Adv"},{"key":"6079_CR4","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/S1470-2045(14)70066-X","volume":"15","author":"SM Ansell","year":"2014","unstructured":"Ansell SM (2014) Follicular lymphoma: watch and wait is watch and worry. Lancet Oncol 15:368\u2013369. https:\/\/doi.org\/10.1016\/S1470-2045(14)70066-X","journal-title":"Lancet Oncol"},{"key":"6079_CR5","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","volume":"15","author":"KM Ardeshna","year":"2014","unstructured":"Ardeshna KM, Qian W, Smith P et al (2014) Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol 15:424\u2013435. https:\/\/doi.org\/10.1016\/S1470-2045(14)70027-0","journal-title":"Lancet Oncol"},{"key":"6079_CR6","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1002\/ajh.26367","volume":"96","author":"M Hallek","year":"2021","unstructured":"Hallek M, Al-Sawaf O (2021) Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol 96:1679\u20131705. https:\/\/doi.org\/10.1002\/ajh.26367","journal-title":"Am J Hematol"},{"issue":"Suppl 1","key":"6079_CR7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/hon.3152","volume":"41","author":"E Zucca","year":"2023","unstructured":"Zucca E, Rossi D, Bertoni F (2023) Marginal zone lymphomas. Hematol Oncol 41(Suppl 1):88\u201391. https:\/\/doi.org\/10.1002\/hon.3152","journal-title":"Hematol Oncol"},{"key":"6079_CR8","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","volume":"32","author":"M Dreyling","year":"2021","unstructured":"Dreyling M, Ghielmini M, Rule S et al (2021) Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals Oncology: Official J Eur Soc Med Oncol 32:298\u2013308. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.008","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"key":"6079_CR9","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G et al (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381:1203\u20131210. https:\/\/doi.org\/10.1016\/S0140-6736(12)61763-2","journal-title":"Lancet"},{"key":"6079_CR10","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/hon.2334","volume":"35","author":"K Laribi","year":"2017","unstructured":"Laribi K, Tempescul A, Ghnaya H et al (2017) The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma. Hematol Oncol 35:536\u2013541. https:\/\/doi.org\/10.1002\/hon.2334","journal-title":"Hematol Oncol"},{"key":"6079_CR11","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/jco.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL et al (2015) Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. J Clin Oncol 33:2516\u20132522. https:\/\/doi.org\/10.1200\/jco.2014.59.7534","journal-title":"J Clin Oncol"},{"key":"6079_CR12","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1200\/JCO.2012.42.4101","volume":"31","author":"OW Press","year":"2013","unstructured":"Press OW, Unger JM, Rimsza LM et al (2013) Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncology: Official J Am Soc Clin Oncol 31:314\u2013320. https:\/\/doi.org\/10.1200\/JCO.2012.42.4101","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"6079_CR13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, Seymour JF, Offner F et al (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet (London England) 377:42\u201351. https:\/\/doi.org\/10.1016\/S0140-6736(10)62175-7","journal-title":"Lancet (London England)"},{"key":"6079_CR14","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1007\/s00277-020-04025-2","volume":"99","author":"C Sortais","year":"2020","unstructured":"Sortais C, Lok A, Tessoulin B et al (2020) Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life. Ann Hematol 99:1595\u20131604. https:\/\/doi.org\/10.1007\/s00277-020-04025-2","journal-title":"Ann Hematol"},{"key":"6079_CR15","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1182\/blood.2019000258","volume":"134","author":"CL Freeman","year":"2019","unstructured":"Freeman CL, Kridel R, Moccia AA et al (2019) Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. Blood 134:761\u2013764. https:\/\/doi.org\/10.1182\/blood.2019000258","journal-title":"Blood"},{"key":"6079_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","volume":"132","author":"E Bachy","year":"2018","unstructured":"Bachy E, Maurer MJ, Habermann TM et al (2018) A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood 132:49\u201358. https:\/\/doi.org\/10.1182\/blood-2017-11-816405","journal-title":"Blood"},{"key":"6079_CR17","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1182\/blood.2020010263","volume":"139","author":"C Casulo","year":"2022","unstructured":"Casulo C, Dixon JG, Le-Rademacher J et al (2022) Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Blood 139:1684\u20131693. https:\/\/doi.org\/10.1182\/blood.2020010263","journal-title":"Blood"},{"key":"6079_CR18","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","volume":"128","author":"V Jurinovic","year":"2016","unstructured":"Jurinovic V, Kridel R, Staiger AM et al (2016) Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood 128:1112\u20131120. https:\/\/doi.org\/10.1182\/blood-2016-05-717355","journal-title":"Blood"},{"key":"6079_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03418-5","author":"W Kuroki","year":"2022","unstructured":"Kuroki W, Kitadate A, Ishiyama K, Kameoka Y, Takahashi N (2022) High baseline total lesion glycolysis predicts early progression of disease within 24 months in patients with high-tumor-burden follicular lymphoma. Int J Hematol. https:\/\/doi.org\/10.1007\/s12185-022-03418-5","journal-title":"Int J Hematol"},{"key":"6079_CR20","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.7150\/jca.54434","volume":"12","author":"SE Yoon","year":"2021","unstructured":"Yoon SE, Cho J, Kim WS, Kim SJ (2021) Impact of transformation on the survival of patients diagnosed with follicular lymphoma that progressed within 24 months. J Cancer 12:2488\u20132497. https:\/\/doi.org\/10.7150\/jca.54434","journal-title":"J Cancer"},{"key":"6079_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18423","author":"A Rajam\u00e4ki","year":"2022","unstructured":"Rajam\u00e4ki A, Hujo M, Sund R et al (2022) Link between disease status at 24 months and mortality in follicular lymphoma. Br J Haematol. https:\/\/doi.org\/10.1111\/bjh.18423","journal-title":"Br J Haematol"},{"key":"6079_CR22","doi-asserted-by":"publisher","first-page":"e838","DOI":"10.1097\/HS9.0000000000000838","volume":"7","author":"CE Weibull","year":"2023","unstructured":"Weibull CE, Wasterlid T, Wahlin BE et al (2023) Survival by First-line Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A National Population-based Study in Sweden. Hemasphere 7:e838. https:\/\/doi.org\/10.1097\/HS9.0000000000000838","journal-title":"Hemasphere"},{"key":"6079_CR23","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1002\/ajh.24492","volume":"91","author":"MJ Maurer","year":"2016","unstructured":"Maurer MJ, Bachy E, Ghesqui\u00e8res H et al (2016) Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol 91:1096\u20131101. https:\/\/doi.org\/10.1002\/ajh.24492","journal-title":"Am J Hematol"},{"key":"6079_CR24","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1002\/cncr.30795","volume":"123","author":"M Provencio","year":"2017","unstructured":"Provencio M, Royuela A, Torrente M et al (2017) Prognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: A study report from the Spanish Lymphoma Oncology Group. Cancer 123:3709\u20133716. https:\/\/doi.org\/10.1002\/cncr.30795","journal-title":"Cancer"},{"key":"6079_CR25","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1200\/JCO.18.00400","volume":"37","author":"C Sarkozy","year":"2019","unstructured":"Sarkozy C, Maurer MJ, Link BK et al (2019) Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts. J Clin Oncol 37:144\u2013152. https:\/\/doi.org\/10.1200\/JCO.18.00400","journal-title":"J Clin Oncol"},{"key":"6079_CR26","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/ajh.25473","volume":"94","author":"SI Tracy","year":"2019","unstructured":"Tracy SI, Larson MC, Feldman AL et al (2019) The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas. Am J Hematol 94:658\u2013666. https:\/\/doi.org\/10.1002\/ajh.25473","journal-title":"Am J Hematol"},{"key":"6079_CR27","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.3324\/haematol.2018.209015","volume":"104","author":"JF Seymour","year":"2019","unstructured":"Seymour JF, Marcus R, Davies A et al (2019) Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. Haematologica 104:1202\u20131208. https:\/\/doi.org\/10.3324\/haematol.2018.209015","journal-title":"Haematologica"},{"key":"6079_CR28","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","volume":"5","author":"A Carbone","year":"2019","unstructured":"Carbone A, Roulland S, Gloghini A et al (2019) Follicular lymphoma. Nat Rev Dis Primers 5:83. https:\/\/doi.org\/10.1038\/s41572-019-0132-x","journal-title":"Nat Rev Dis Primers"},{"key":"6079_CR29","first-page":"83","volume":"102","author":"E Sabattini","year":"2010","unstructured":"Sabattini E, Bacci F, Sagramoso C, Pileri SA (2010) WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica 102:83\u201387","journal-title":"Pathologica"},{"key":"6079_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19213","author":"T Watanabe","year":"2023","unstructured":"Watanabe T, Tobinai K, Wakabayashi M et al (2023) R-CHOP treatment for patients with advanced follicular lymphoma: Over 15-year follow-up of JCOG0203. Br J Haematol. https:\/\/doi.org\/10.1111\/bjh.19213","journal-title":"Br J Haematol"},{"key":"6079_CR31","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/jnci\/djk152","volume":"99","author":"H Schulz","year":"2007","unstructured":"Schulz H, Bohlius JF, Trelle S et al (2007) Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 99:706\u2013714","journal-title":"J Natl Cancer Inst"},{"key":"6079_CR32","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1200\/JCO.18.00605","volume":"37","author":"IW Flinn","year":"2019","unstructured":"Flinn IW, van der Jagt R, Kahl B et al (2019) First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study. J Clin Oncol 37:984\u2013991. https:\/\/doi.org\/10.1200\/JCO.18.00605","journal-title":"J Clin Oncol"},{"key":"6079_CR33","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1634\/theoncologist.2017-0037","volume":"23","author":"P Mondello","year":"2018","unstructured":"Mondello P, Steiner N, Willenbacher W et al (2018) Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study. Oncologist 23:454\u2013460. https:\/\/doi.org\/10.1634\/theoncologist.2017-0037","journal-title":"Oncologist"},{"key":"6079_CR34","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.6004\/jnccn.2019.5038","volume":"17","author":"RI Fisher","year":"2019","unstructured":"Fisher RI (2019) Optimizing First-Line Therapy for Follicular Lymphoma: Is It Time for Chemotherapy-Free Approaches? J Natl Compr Canc Netw 17:1414\u20131416. https:\/\/doi.org\/10.6004\/jnccn.2019.5038","journal-title":"J Natl Compr Canc Netw"},{"key":"6079_CR35","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","volume":"377","author":"R Marcus","year":"2017","unstructured":"Marcus R, Davies A, Ando K et al (2017) Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med 377:1331\u20131344. https:\/\/doi.org\/10.1056\/NEJMoa1614598","journal-title":"N Engl J Med"},{"key":"6079_CR36","unstructured":"https:\/\/www.nccn.org\/patients\/guidelines\/content\/PDF\/nhl-follicular-patient.pdf"},{"key":"6079_CR37","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1200\/jco.18.00262","volume":"36","author":"S Lockmer","year":"2018","unstructured":"Lockmer S, \u00d8stenstad B, Hagberg H et al (2018) Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up. J Clin Oncol 36:3315\u20133323. https:\/\/doi.org\/10.1200\/jco.18.00262","journal-title":"J Clin Oncol"},{"key":"6079_CR38","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1111\/bjh.17045","volume":"192","author":"AA Moccia","year":"2021","unstructured":"Moccia AA, Sch\u00e4r S, Hayoz S et al (2021) Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK). Br J Haematol 192:1031\u20131034. https:\/\/doi.org\/10.1111\/bjh.17045","journal-title":"Br J Haematol"},{"key":"6079_CR39","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/S1470-2045(14)70455-3","volume":"15","author":"NH Fowler","year":"2014","unstructured":"Fowler NH, Davis RE, Rawal S et al (2014) Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 15:1311\u20131318. https:\/\/doi.org\/10.1016\/S1470-2045(14)70455-3","journal-title":"Lancet Oncol"},{"key":"6079_CR40","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1200\/JCO.22.00843","volume":"40","author":"F Morschhauser","year":"2022","unstructured":"Morschhauser F, Nastoupil L, Feugier P et al (2022) Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R(2)) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma. J Clin Oncol 40:3239\u20133245. https:\/\/doi.org\/10.1200\/JCO.22.00843","journal-title":"J Clin Oncol"},{"key":"6079_CR41","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/cam4.1918","volume":"8","author":"F Lansigan","year":"2019","unstructured":"Lansigan F, Barak I, Pitcher B et al (2019) The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials. Cancer Med 8:165\u2013173. https:\/\/doi.org\/10.1002\/cam4.1918","journal-title":"Cancer Med"},{"key":"6079_CR42","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.3324\/haematol.2020.246991","volume":"105","author":"JF Seymour","year":"2020","unstructured":"Seymour JF, Marcus R, Davies A et al (2020) Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. Haematologica 105:1465. https:\/\/doi.org\/10.3324\/haematol.2020.246991","journal-title":"Haematologica"},{"key":"6079_CR43","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1093\/annonc\/mdw026","volume":"27","author":"CY Cheah","year":"2016","unstructured":"Cheah CY, Chihara D, Ahmed M et al (2016) Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Ann Oncol 27:895\u2013901. https:\/\/doi.org\/10.1093\/annonc\/mdw026","journal-title":"Ann Oncol"},{"key":"6079_CR44","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/hon.44_2630","volume":"37","author":"MJ Maurer","year":"2019","unstructured":"Maurer MJ, Jakopsen LH, Habermann TM et al (2019) OUTCOMES AFTER EARLY TRANSFORMATION (tPOD24) VS. EARLY FOLLICULAR LYMPHOMA PROGRESSION (fPOD24) IN FOLLICULAR LYMPHOMA TREATED WITH FRONTLINE IMMUNOCHEMOTHERAPY. Hematol Oncol 37:231\u2013232. https:\/\/doi.org\/10.1002\/hon.44_2630","journal-title":"Hematol Oncol"},{"key":"6079_CR45","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/bjh.18522","volume":"200","author":"A Muntanola","year":"2023","unstructured":"Muntanola A, Mozas P, Mercadal S et al (2023) Early progression in follicular lymphoma in the absence of histological transformation or high-risk Follicular Lymphoma International Prognostic Index still has a favourable outcome. Br J Haematol 200:306\u2013314. https:\/\/doi.org\/10.1111\/bjh.18522","journal-title":"Br J Haematol"},{"key":"6079_CR46","doi-asserted-by":"publisher","unstructured":"Cerhan JR, Habermann TM (2021) Epidemiology of Marginal Zone Lymphoma. Ann Lymphoma 5. https:\/\/doi.org\/10.21037\/aol-20-28","DOI":"10.21037\/aol-20-28"},{"key":"6079_CR47","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/cncr.27773","volume":"119","author":"AJ Olszewski","year":"2013","unstructured":"Olszewski AJ, Castillo JJ (2013) Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database. Cancer 119:629\u2013638. https:\/\/doi.org\/10.1002\/cncr.27773","journal-title":"Cancer"},{"key":"6079_CR48","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1182\/blood.2019001088","volume":"134","author":"S Luminari","year":"2019","unstructured":"Luminari S, Merli M, Rattotti S et al (2019) Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study. Blood 134:798\u2013801. https:\/\/doi.org\/10.1182\/blood.2019001088","journal-title":"Blood"},{"key":"6079_CR49","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.3324\/haematol.2019.237990","volume":"105","author":"A Conconi","year":"2020","unstructured":"Conconi A, Thieblemont C, Cascione L et al (2020) Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment. Haematologica 105:2592\u20132597. https:\/\/doi.org\/10.3324\/haematol.2019.237990","journal-title":"Haematologica"},{"key":"6079_CR50","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3760\/cma.j.issn.0253-2727.2020.03.008","volume":"41","author":"R Lyu","year":"2020","unstructured":"Lyu R, Yan YT, Yi SH et al (2020) [The prognostic significance of POD24 in 106 cases with splenic marginal lymphoma with bone marrow invasion]. Zhonghua Xue Ye Xue Za Zhi 41:228\u2013233. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2020.03.008","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"6079_CR51","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1182\/blood-2022-166785","volume":"140","author":"N Epperla","year":"2022","unstructured":"Epperla N, Li R, Torka P et al (2022) Early Relapse within 24 Months after Frontline Systemic Therapy (POD24) Is Associated with Worse Survival in Patients with Marginal Zone Lymphoma: A US Multisite Study. Blood 140:1926\u20131928. https:\/\/doi.org\/10.1182\/blood-2022-166785","journal-title":"Blood"},{"key":"6079_CR52","first-page":"927","volume":"78","author":"J Waldenstrom","year":"1948","unstructured":"Waldenstrom J (1948) [Two interesting Syndromes with Hyperglobulemia (purpura hyperglobulinemia and Macroglobulinemia)]. Schweiz Med Wochenschr 78:927","journal-title":"Schweiz Med Wochenschr"},{"key":"6079_CR53","doi-asserted-by":"publisher","first-page":"801124","DOI":"10.3389\/fonc.2021.801124","volume":"11","author":"F Piazza","year":"2021","unstructured":"Piazza F, Di Paolo V, Scapinello G et al (2021) Determinants of Drug Resistance in B-Cell Non-Hodgkin Lymphomas: The Case of Lymphoplasmacytic Lymphoma\/Waldenstrom Macroglobulinemia. Front Oncol 11:801124. https:\/\/doi.org\/10.3389\/fonc.2021.801124","journal-title":"Front Oncol"},{"key":"6079_CR54","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1182\/blood-2008-08-174961","volume":"113","author":"P Morel","year":"2009","unstructured":"Morel P, Duhamel A, Gobbi P et al (2009) International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 113:4163\u20134170. https:\/\/doi.org\/10.1182\/blood-2008-08-174961","journal-title":"Blood"},{"key":"6079_CR55","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1182\/bloodadvances.2018021287","volume":"2","author":"S Guidez","year":"2018","unstructured":"Guidez S, Labreuche J, Drumez E et al (2018) Onsets of progression and second treatment determine survival of patients with symptomatic Waldenstr\u00f6m macroglobulinemia. Blood Adv 2:3102\u20133111. https:\/\/doi.org\/10.1182\/bloodadvances.2018021287","journal-title":"Blood Adv"},{"key":"6079_CR56","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/hon.2996","volume":"40","author":"J Labreuche","year":"2022","unstructured":"Labreuche J, Assouan D, Durot E et al (2022) Does early disease progression predict survival after first line-treatment of Waldenstr\u00f6m macroglobulinemia? Hematol Oncol 40:400\u2013408. https:\/\/doi.org\/10.1002\/hon.2996","journal-title":"Hematol Oncol"},{"key":"6079_CR57","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D et al (2018) iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131:2745\u20132760. https:\/\/doi.org\/10.1182\/blood-2017-09-806398","journal-title":"Blood"},{"key":"6079_CR58","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I et al (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 36:1720\u20131748. https:\/\/doi.org\/10.1038\/s41375-022-01620-2","journal-title":"Leukemia"},{"key":"6079_CR59","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2023.1946","volume":"329","author":"M Shadman","year":"2023","unstructured":"Shadman M (2023) Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review. JAMA 329:918\u2013932. https:\/\/doi.org\/10.1001\/jama.2023.1946","journal-title":"JAMA"},{"key":"6079_CR60","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1182\/bloodadvances.2017011262","volume":"1","author":"IE Ahn","year":"2017","unstructured":"Ahn IE, Farber CM, Davids MS et al (2017) Early progression of disease as a predictor of survival in chronic lymphocytic leukemia. Blood Adv 1:2433\u20132443. https:\/\/doi.org\/10.1182\/bloodadvances.2017011262","journal-title":"Blood Adv"},{"key":"6079_CR61","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1080\/10428194.2022.2148218","volume":"64","author":"KS Bantilan","year":"2023","unstructured":"Bantilan KS, Kay NE, Parikh SA et al (2023) Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection. Leuk Lymphoma 64:300\u2013311. https:\/\/doi.org\/10.1080\/10428194.2022.2148218","journal-title":"Leuk Lymphoma"},{"key":"6079_CR62","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","volume":"388","author":"B Eichhorst","year":"2023","unstructured":"Eichhorst B, Niemann CU, Kater AP et al (2023) First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia. N Engl J Med 388:1739\u20131754. https:\/\/doi.org\/10.1056\/NEJMoa2213093","journal-title":"N Engl J Med"},{"key":"6079_CR63","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMoa1817073","volume":"381","author":"TD Shanafelt","year":"2019","unstructured":"Shanafelt TD, Wang XV, Kay NE et al (2019) Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. N Engl J Med 381:432\u2013443. https:\/\/doi.org\/10.1056\/NEJMoa1817073","journal-title":"N Engl J Med"},{"key":"6079_CR64","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/j.clml.2017.07.004","volume":"17","author":"EM Ammann","year":"2017","unstructured":"Ammann EM, Shanafelt TD, Larson MC et al (2017) Time to Second-line Treatment and Subsequent Relative Survival in Older Patients With Relapsed Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma. Clin Lymphoma Myeloma Leuk 17:e11\u2013e25. https:\/\/doi.org\/10.1016\/j.clml.2017.07.004","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6079_CR65","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-Celigny","year":"2004","unstructured":"Solal-Celigny P, Roy P, Colombat P et al (2004) Follicular lymphoma international prognostic index. Blood 104:1258\u20131265. https:\/\/doi.org\/10.1182\/blood-2003-12-4434","journal-title":"Blood"},{"key":"6079_CR66","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1002\/ajh.26737","volume":"97","author":"E Jacobsen","year":"2022","unstructured":"Jacobsen E (2022) Follicular lymphoma: 2023 update on diagnosis and management. Am J Hematol 97:1638\u20131651. https:\/\/doi.org\/10.1002\/ajh.26737","journal-title":"Am J Hematol"},{"key":"6079_CR67","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1182\/blood-2006-01-013367","volume":"108","author":"C Buske","year":"2006","unstructured":"Buske C, Hoster E, Dreyling M et al (2006) The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 108:1504\u20131508. https:\/\/doi.org\/10.1182\/blood-2006-01-013367","journal-title":"Blood"},{"key":"6079_CR68","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/annonc\/mds429","volume":"24","author":"AK Nooka","year":"2013","unstructured":"Nooka AK, Nabhan C, Zhou X et al (2013) Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. Ann Oncol 24:441\u2013448. https:\/\/doi.org\/10.1093\/annonc\/mds429","journal-title":"Ann Oncol"},{"key":"6079_CR69","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1182\/bloodadvances.2022007949","volume":"7","author":"JJ Rodr\u00edguez-Sevilla","year":"2023","unstructured":"Rodr\u00edguez-Sevilla JJ, Fern\u00e1ndez-Rodr\u00edguez C, Bento L et al (2023) Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy. Blood Adv 7:1606\u20131614. https:\/\/doi.org\/10.1182\/bloodadvances.2022007949","journal-title":"Blood Adv"},{"key":"6079_CR70","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.beha.2017.11.002","volume":"31","author":"C Casulo","year":"2018","unstructured":"Casulo C (2018) Risk stratification in follicular lymphoma. Best Pract Res Clin Haematol 31:15\u201322. https:\/\/doi.org\/10.1016\/j.beha.2017.11.002","journal-title":"Best Pract Res Clin Haematol"},{"key":"6079_CR71","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","volume":"27","author":"M Federico","year":"2009","unstructured":"Federico M, Bellei M, Marcheselli L et al (2009) Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 27:4555\u20134562. https:\/\/doi.org\/10.1200\/JCO.2008.21.3991","journal-title":"J Clin Oncol"},{"key":"6079_CR72","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.1365-2141.2009.08065.x","volume":"149","author":"L Arcaini","year":"2010","unstructured":"Arcaini L, Merli M, Passamonti F et al (2010) Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients. Br J Haematol 149:455\u2013457. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.08065.x","journal-title":"Br J Haematol"},{"key":"6079_CR73","doi-asserted-by":"publisher","first-page":"6624","DOI":"10.1158\/1078-0432.CCR-13-1120","volume":"19","author":"OW Press","year":"2013","unstructured":"Press OW, Unger JM, Rimsza LM et al (2013) A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP\u2009+\u2009131iodine\u2013tositumomab. Clin Cancer Res 19:6624\u20136632. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-1120","journal-title":"Clin Cancer Res"},{"key":"6079_CR74","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/bjh.16692","volume":"191","author":"E Kimby","year":"2020","unstructured":"Kimby E, Lockmer S, Holte H et al (2020) The simplified follicular lymphoma PRIMA-prognostic index is useful in patients with first-line chemo-free rituximab-based therapy. Br J Haematol 191:738\u2013747. https:\/\/doi.org\/10.1111\/bjh.16692","journal-title":"Br J Haematol"},{"key":"6079_CR75","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1002\/ajh.25973","volume":"95","author":"F Mir","year":"2020","unstructured":"Mir F, Mattiello F, Grigg A et al (2020) Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy. Am J Hematol 95:1503\u20131510. https:\/\/doi.org\/10.1002\/ajh.25973","journal-title":"Am J Hematol"},{"key":"6079_CR76","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/s1470-2045(15)00169-2","volume":"16","author":"A Pastore","year":"2015","unstructured":"Pastore A, Jurinovic V, Kridel R et al (2015) Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol 16:1111\u20131122. https:\/\/doi.org\/10.1016\/s1470-2045(15)00169-2","journal-title":"Lancet Oncol"},{"key":"6079_CR77","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1470-2045(18)30102-5","volume":"19","author":"S Huet","year":"2018","unstructured":"Huet S, Tesson B, Jais JP et al (2018) A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Lancet Oncol 19:549\u2013561","journal-title":"Lancet Oncol"},{"key":"6079_CR78","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1182\/blood-2017-03-771915","volume":"130","author":"C Thieblemont","year":"2017","unstructured":"Thieblemont C, Cascione L, Conconi A et al (2017) A MALT lymphoma prognostic index. Blood 130:1409\u20131417. https:\/\/doi.org\/10.1182\/blood-2017-03-771915","journal-title":"Blood"},{"key":"6079_CR79","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1002\/ajh.26715","volume":"97","author":"JP Alderuccio","year":"2022","unstructured":"Alderuccio JP, Reis IM, Habermann TM et al (2022) Revised MALT-IPI: A new predictive model that identifies high-risk patients with extranodal marginal zone lymphoma. Am J Hematol 97:1529\u20131537. https:\/\/doi.org\/10.1002\/ajh.26715","journal-title":"Am J Hematol"},{"key":"6079_CR80","doi-asserted-by":"publisher","first-page":"102592","DOI":"10.1016\/j.eclinm.2024.102592","volume":"72","author":"L Arcaini","year":"2024","unstructured":"Arcaini L, Bommier C, Alderuccio JP et al (2024) Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment. EClinicalMedicine 72:102592. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102592","journal-title":"EClinicalMedicine"},{"key":"6079_CR81","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1182\/blood-2008-08-174961","volume":"113","author":"P Morel","year":"2009","unstructured":"Morel P, Duhamel A, Gobbi P et al (2009) International prognostic scoring system for Waldenstr\u00f6m macroglobulinemia. Blood 113:4163\u20134170. https:\/\/doi.org\/10.1182\/blood-2008-08-174961","journal-title":"Blood"},{"key":"6079_CR82","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1038\/s41375-019-0431-y","volume":"33","author":"E Kastritis","year":"2019","unstructured":"Kastritis E, Morel P, Duhamel A et al (2019) A revised international prognostic score system for Waldenstr\u00f6m\u2019s macroglobulinemia. Leukemia 33:2654\u20132661. https:\/\/doi.org\/10.1038\/s41375-019-0431-y","journal-title":"Leukemia"},{"key":"6079_CR83","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/ajh.24955","volume":"93","author":"JP Abeykoon","year":"2018","unstructured":"Abeykoon JP, Paludo J, King RL et al (2018) MYD88 mutation status does not impact overall survival in Waldenstr\u00f6m macroglobulinemia. Am J Hematol 93:187\u2013194. https:\/\/doi.org\/10.1002\/ajh.24955","journal-title":"Am J Hematol"},{"key":"6079_CR84","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1200\/JCO.23.02066","volume":"42","author":"S Zanwar","year":"2024","unstructured":"Zanwar S, Le-Rademacher J, Durot E et al (2024) Simplified Risk Stratification Model for Patients With Waldenstrom Macroglobulinemia. J Clin Oncol 42:2527\u20132536. https:\/\/doi.org\/10.1200\/JCO.23.02066","journal-title":"J Clin Oncol"},{"key":"6079_CR85","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/s1470-2045(16)30029-8","volume":"17","author":"An international prognostic","year":"2016","unstructured":"An international prognostic (2016) index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol 17:779\u2013790. https:\/\/doi.org\/10.1016\/s1470-2045(16)30029-8","journal-title":"Lancet Oncol"},{"key":"6079_CR86","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1182\/blood.2023022564","volume":"143","author":"P Langerbeins","year":"2024","unstructured":"Langerbeins P, Giza A, Robrecht S et al (2024) Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies. Blood 143:2588\u20132598. https:\/\/doi.org\/10.1182\/blood.2023022564","journal-title":"Blood"},{"key":"6079_CR87","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1200\/jco.20.00979","volume":"39","author":"IE Ahn","year":"2021","unstructured":"Ahn IE, Tian X, Ipe D et al (2021) Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model. J Clin Oncol 39:576\u2013585. https:\/\/doi.org\/10.1200\/jco.20.00979","journal-title":"J Clin Oncol"},{"key":"6079_CR88","doi-asserted-by":"publisher","first-page":"e366","DOI":"10.1016\/s2352-3026(19)30085-7","volume":"6","author":"JD Soumerai","year":"2019","unstructured":"Soumerai JD, Ni A, Darif M et al (2019) Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. Lancet Haematol 6:e366\u2013e374. https:\/\/doi.org\/10.1016\/s2352-3026(19)30085-7","journal-title":"Lancet Haematol"},{"key":"6079_CR89","doi-asserted-by":"publisher","unstructured":"Hu J, Gao F, Zhao J et al (2023) The prognostic index PRIMA-PI combined with Ki67 as a better predictor of progression of disease within 24 months in follicular lymphoma. Front Oncol 13. https:\/\/doi.org\/10.3389\/fonc.2023.1090610","DOI":"10.3389\/fonc.2023.1090610"},{"key":"6079_CR90","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1182\/blood-2020-142000","volume":"136","author":"W Wu","year":"2020","unstructured":"Wu W, Bruscaggin A, Valera A et al (2020) Evaluation of the Different Stratification Models for POD24 Prediction in Patients with Follicular Lymphoma. Blood 136:24\u201325. https:\/\/doi.org\/10.1182\/blood-2020-142000","journal-title":"Blood"},{"key":"6079_CR91","doi-asserted-by":"crossref","unstructured":"Hiddemann W, Kneba M, Dreyling M et al (2005) Frontline therapy with rituximabadded to the combination of cyclophosphamide, doxorubicin, vincristine, andprednisone (CHOP) significantly improves the outcome for patients withadvanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade LymphomaStudy Group. Blood 106:3725\u20133732","DOI":"10.1182\/blood-2005-01-0016"},{"key":"6079_CR92","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1182\/blood-2022-157194","volume":"140","author":"MJ Maurer","year":"2022","unstructured":"Maurer MJ, Prochazka VK, Flowers CR et al (2022) FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma. Blood 140:2292\u20132295. https:\/\/doi.org\/10.1182\/blood-2022-157194","journal-title":"Blood"},{"key":"6079_CR93","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.1200\/jco.18.02365","volume":"37","author":"JWD Tobin","year":"2019","unstructured":"Tobin JWD, Keane C, Gunawardana J et al (2019) Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration. J Clin Oncol 37:3300\u20133309. https:\/\/doi.org\/10.1200\/jco.18.02365","journal-title":"J Clin Oncol"},{"key":"6079_CR94","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","volume":"123","author":"S Stilgenbauer","year":"2014","unstructured":"Stilgenbauer S, Schnaiter A, Paschka P et al (2014) Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 123:3247\u20133254. https:\/\/doi.org\/10.1182\/blood-2014-01-546150","journal-title":"Blood"},{"key":"6079_CR95","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nature15395","volume":"526","author":"DA Landau","year":"2015","unstructured":"Landau DA, Tausch E, Taylor-Weiner AN et al (2015) Mutations driving CLL and their evolution in progression and relapse. Nature 526:525\u2013530. https:\/\/doi.org\/10.1038\/nature15395","journal-title":"Nature"},{"key":"6079_CR96","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18974","author":"F Gao","year":"2023","unstructured":"Gao F, Liu H, Meng X et al (2023) Integrative genomic and transcriptomic analysis reveals genetic alterations associated with the early progression of follicular lymphoma. Br J Haematol. https:\/\/doi.org\/10.1111\/bjh.18974","journal-title":"Br J Haematol"},{"key":"6079_CR97","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41408-024-01124-5","volume":"14","author":"B Bai","year":"2024","unstructured":"Bai B, Wise JF, Vodak D et al (2024) Multi-omics profiling of longitudinal samples reveals early genomic changes in follicular lymphoma. Blood Cancer J 14:147. https:\/\/doi.org\/10.1038\/s41408-024-01124-5","journal-title":"Blood Cancer J"},{"key":"6079_CR98","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1080\/10428194.2021.1872073","volume":"62","author":"A Rajam\u00e4ki","year":"2021","unstructured":"Rajam\u00e4ki A, Sunela K, Prusila REI et al (2021) Female patients with follicular lymphoma have a better prognosis if primary remission lasts over 24 months. Leuk Lymphoma 62:1639\u20131647. https:\/\/doi.org\/10.1080\/10428194.2021.1872073","journal-title":"Leuk Lymphoma"},{"key":"6079_CR99","doi-asserted-by":"publisher","first-page":"6685","DOI":"10.21873\/anticanres.14692","volume":"40","author":"A Szumera-Cie\u0106kiewicz","year":"2020","unstructured":"Szumera-Cie\u0106kiewicz A, Poleszczuk J, Paszkiewicz-Kozik E et al (2020) EZH2 Expression in Follicular Lymphoma Is Variable and Independent from the Progression of Disease Within 24 Months of First Treatment. Anticancer Res 40:6685\u20136697. https:\/\/doi.org\/10.21873\/anticanres.14692","journal-title":"Anticancer Res"},{"key":"6079_CR100","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04914-8","author":"F Gao","year":"2022","unstructured":"Gao F, Zhang T, Liu H et al (2022) Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis. Ann Hematol. https:\/\/doi.org\/10.1007\/s00277-022-04914-8","journal-title":"Ann Hematol"},{"key":"6079_CR101","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1182\/blood.2022017411","volume":"141","author":"PJ Hengeveld","year":"2023","unstructured":"Hengeveld PJ, van der Klift MY, Kolijn PM et al (2023) Detecting measurable residual disease beyond 10\u2009\u2013\u20094 by an IGHV leader-based NGS approach improves prognostic stratification in CLL. Blood 141:519\u2013528. https:\/\/doi.org\/10.1182\/blood.2022017411","journal-title":"Blood"},{"key":"6079_CR102","doi-asserted-by":"publisher","first-page":"5179","DOI":"10.1182\/bloodadvances.2021004765","volume":"5","author":"DA Bond","year":"2021","unstructured":"Bond DA, Switchenko JM, Villa D et al (2021) Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. Blood Adv 5:5179\u20135189. https:\/\/doi.org\/10.1182\/bloodadvances.2021004765","journal-title":"Blood Adv"},{"key":"6079_CR103","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1097\/hs9.0000000000000510","volume":"5","author":"CW Eskelund","year":"2021","unstructured":"Eskelund CW, Dimopoulos K, Kolstad A et al (2021) Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3. Hemasphere 5:e510. https:\/\/doi.org\/10.1097\/hs9.0000000000000510","journal-title":"Hemasphere"},{"key":"6079_CR104","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41375-020-01013-3","volume":"35","author":"C Visco","year":"2021","unstructured":"Visco C, Di Rocco A, Evangelista A et al (2021) Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. Leukemia 35:787\u2013795. https:\/\/doi.org\/10.1038\/s41375-020-01013-3","journal-title":"Leukemia"},{"key":"6079_CR105","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1182\/blood-2021-147538","volume":"138","author":"Y Wang","year":"2021","unstructured":"Wang Y, Larson MC, Castellino A et al (2021) Event-Free Survival at 24 Months (EFS24) Becomes an Important Clinical Endpoint in Newly Diagnosed Mantle Cell Lymphoma in the New Era. Blood 138:2429\u20132429. https:\/\/doi.org\/10.1182\/blood-2021-147538","journal-title":"Blood"},{"key":"6079_CR106","doi-asserted-by":"publisher","first-page":"5662","DOI":"10.1038\/s41598-022-09539-5","volume":"12","author":"Y-H Wang","year":"2022","unstructured":"Wang Y-H, Hsieh C-Y, Hsiao L-T et al (2022) Stem cell transplant for mantle cell lymphoma in Taiwan. Sci Rep 12:5662. https:\/\/doi.org\/10.1038\/s41598-022-09539-5","journal-title":"Sci Rep"},{"key":"6079_CR107","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18597","author":"M Harmanen","year":"2022","unstructured":"Harmanen M, Hujo M, Sund R et al (2022) Survival of patients with mantle cell lymphoma in the rituximab era: Retrospective binational analysis between 2000 and 2020. Br J Haematol. https:\/\/doi.org\/10.1111\/bjh.18597","journal-title":"Br J Haematol"},{"key":"6079_CR108","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1111\/bjh.15643","volume":"185","author":"C Visco","year":"2019","unstructured":"Visco C, Tisi MC, Evangelista A et al (2019) Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death. Br J Haematol 185:940\u2013944. https:\/\/doi.org\/10.1111\/bjh.15643","journal-title":"Br J Haematol"},{"key":"6079_CR109","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1200\/jco.2013.51.5866","volume":"32","author":"MJ Maurer","year":"2014","unstructured":"Maurer MJ, Ghesqui\u00e8res H, Jais JP et al (2014) Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol 32:1066\u20131073. https:\/\/doi.org\/10.1200\/jco.2013.51.5866","journal-title":"J Clin Oncol"},{"key":"6079_CR110","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s12185-020-02987-7","volume":"112","author":"Y Suzuki","year":"2020","unstructured":"Suzuki Y, Yano T, Suehiro Y et al (2020) Evaluation of prognosis following early disease progression in peripheral T-cell lymphoma. Int J Hematol 112:817\u2013824. https:\/\/doi.org\/10.1007\/s12185-020-02987-7","journal-title":"Int J Hematol"},{"key":"6079_CR111","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1002\/cncr.31374","volume":"124","author":"SM Smith","year":"2018","unstructured":"Smith SM, Godfrey J, Ahn KW et al (2018) Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. Cancer 124:2541\u20132551. https:\/\/doi.org\/10.1002\/cncr.31374","journal-title":"Cancer"},{"key":"6079_CR112","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41408-021-00539-8","volume":"11","author":"F Morschhauser","year":"2021","unstructured":"Morschhauser F, Ghosh N, Lossos IS et al (2021) Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed\/refractory follicular lymphoma: final analysis of a Phase Ib\/II trial. Blood Cancer J 11:147. https:\/\/doi.org\/10.1038\/s41408-021-00539-8","journal-title":"Blood Cancer J"},{"key":"6079_CR113","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1182\/blood-2016-12-757740","volume":"129","author":"AK Gopal","year":"2017","unstructured":"Gopal AK, Kahl BS, Flowers CR et al (2017) Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. Blood 129:3037\u20133039. https:\/\/doi.org\/10.1182\/blood-2016-12-757740","journal-title":"Blood"},{"key":"6079_CR114","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.bbmt.2017.12.771","volume":"24","author":"C Casulo","year":"2018","unstructured":"Casulo C, Friedberg JW, Ahn KW et al (2018) Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. Biol Blood Marrow Transpl 24:1163\u20131171. https:\/\/doi.org\/10.1016\/j.bbmt.2017.12.771","journal-title":"Biol Blood Marrow Transpl"},{"key":"6079_CR115","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","volume":"28","author":"NH Fowler","year":"2022","unstructured":"Fowler NH, Dickinson M, Dreyling M et al (2022) Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med 28:325\u2013332. https:\/\/doi.org\/10.1038\/s41591-021-01622-0","journal-title":"Nat Med"},{"key":"6079_CR116","doi-asserted-by":"publisher","first-page":"5835","DOI":"10.1182\/bloodadvances.2022008150","volume":"6","author":"G Salles","year":"2022","unstructured":"Salles G, Schuster SJ, Dreyling M et al (2022) Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma. Blood Adv 6:5835\u20135843. https:\/\/doi.org\/10.1182\/bloodadvances.2022008150","journal-title":"Blood Adv"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06079-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06079-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06079-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T10:09:58Z","timestamp":1745575798000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06079-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,16]]},"references-count":116,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["6079"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06079-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,16]]},"assertion":[{"value":"28 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of Competing Interest"}}]}}